Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma(HCC) in patients chronically infected with hepatitis B virus(HBV) or hepatitis C virus(HCV). The approved medicatio...Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma(HCC) in patients chronically infected with hepatitis B virus(HBV) or hepatitis C virus(HCV). The approved medication for the treatment of chronic HBV infection is interferon-α(IFNα) and nucleos(t)ide analogues(NAs), including lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir disoproxil fumarate. IFNα is the most suitable for young patients with less advanced liver diseases and those infected with HBV genotype A. IFNα treatment significantly decreases the overall incidence of HBV-related HCC in sustained responders. However, side effects may limit its long-term clinical application. Orally administered NAs are typically implemented for patients with more advanced liver diseases. NA treatment significantly reduces disease progression of cirrhosis and therefore HCC incidence, especially in HBV e antigen-positive patients. NA-resistance due to the mutations in HBV polymerase is a major limiting factor. Of the NA resistance-associated mutants, A181 T mutant significantly increases the risk of HCC development during the subsequent course of NA therapy. It is important to initiate treatment with NAs that have a high genetic barrier to resistance, to counsel patients on medication adherence and to monitor virological breakthroughs. The recommended treatment for patients with chronic HCV infection is peg-IFN plus ribavirin that can decrease the occurrence of HCC in those who achieve a sustained virological response and have not yet progressed to cirrhosis. IFN-based treatment is reserved for patients with decompensated cirrhosis who are under evaluation of liver transplantation to reduce post-transplant recurrence of HCV. More effective therapeutic options such as direct acting antiviral agents will hopefully increase the response rate in difficult-totreat patients with HCV genotype 1. However, the risk of HCC remains in cirrhotic patients(both chronic HBV and HCV infection) if treatment is initiated after cirrhosis is established. Future research should focus on investigating new agents, especially for those patients with hepatic decompensation or post-transplantation.展开更多
The structure and electrochemical properties of the La0.7Mg0.3Ni3.4-xMn0.1Cox （x=01.05） hydrogen storage alloys were investigated. The crystal structure and the lattice parameters of the alloys were analyzed by X-ra...The structure and electrochemical properties of the La0.7Mg0.3Ni3.4-xMn0.1Cox （x=01.05） hydrogen storage alloys were investigated. The crystal structure and the lattice parameters of the alloys were analyzed by X-ray diffractometry and Rietveld method. Electrochemical properties of the alloys including p—c—t curves, discharge capacity, discharge capacity retention were studied. The results show that （La, Mg）Ni3 and LaNi5 are the main phases of all the alloys. The plateau pressure for hydrogen absorption/desorption decreases and the hydrogen storage capacity firstly increases and subsequently decreases with increasing Co content. The values of the maximum discharge capacity of the alloy electrodes remain in range of 395.3403.1mA·h/g in spite of the change of Co content. The cycling stability of the alloy electrodes is greatly improved with increasing Co content, which is attributed to the suppression of the cell volume expansion during hydriding, leading the pulverization of the alloy particles lowered and the oxidation/corrosion of the active elements reduced.展开更多
针对测地线活动轮廓(geodesic active contour,GAC)模型轮廓演化速度慢的问题,构造一个区域灰度相似性信息项,对GAC模型的能量泛函进行改进,加快轮廓演化速度,将其用于肺部薄扫CT(computed tomography)图像序列中肺实质的自动分割。采...针对测地线活动轮廓(geodesic active contour,GAC)模型轮廓演化速度慢的问题,构造一个区域灰度相似性信息项,对GAC模型的能量泛函进行改进,加快轮廓演化速度,将其用于肺部薄扫CT(computed tomography)图像序列中肺实质的自动分割。采用基于Nystrom逼近的谱聚类算法分割CT图像序列中间位置CT中的肺实质,计算其灰度均值与标准差,构造区域灰度相似性信息项,以分割好的肺实质轮廓作为初始轮廓,分别从上下两个方向采用改进了能量泛函的GAC模型实现其它切片中肺实质的分割。实验结果表明,该方法能够较好实现肺实质的自动分割,与医师分割结果的重合率可达94.83%,时间消耗较少。展开更多
目的探讨16排螺旋CT行胸部血管造影检查时图像质量与碘造影剂注射流速的相关性。方法选取自2013年10月—2016年9月在该科行胸部CT检查老年患者90例,随机分为A1、A2、A3 3组,每组30例。3组流速分别为2.0~2.4、2.5~2.8、2.9~3.2 m L/s。...目的探讨16排螺旋CT行胸部血管造影检查时图像质量与碘造影剂注射流速的相关性。方法选取自2013年10月—2016年9月在该科行胸部CT检查老年患者90例,随机分为A1、A2、A3 3组,每组30例。3组流速分别为2.0~2.4、2.5~2.8、2.9~3.2 m L/s。观察分析肺动脉平均强化值,图像质量。结果 3组行CT检查后的效果评价A1,A2,A3组的肺动脉平均强化值分别为(195.9±29.1),(262.20±59.0),(255.9±53.2),3组造影效果主动脉强化值差异有统计学意义(P<0.01),3组不同流速碘造影剂的图像质量差异有统计学意义(P<0.01)。结论老年患者在行胸部CT增强扫描碘造影剂注射流速在2.5~2.8 m L/s时,获得的图像较满意,并能满足临床诊断需要,且能保护患者穿刺血管的安全。展开更多
随着无线通信技术的发展,车载自组织网络(Vehicular Ad Hoc Network,VANET)已经成为一个新型的研究领域。针对VANET中车辆行驶的特征以及车辆间安全信息传输严格的时延限制和高可靠性要求,提出了一种基于簇的协作MAC(CCB-MAC)协议用于...随着无线通信技术的发展,车载自组织网络(Vehicular Ad Hoc Network,VANET)已经成为一个新型的研究领域。针对VANET中车辆行驶的特征以及车辆间安全信息传输严格的时延限制和高可靠性要求,提出了一种基于簇的协作MAC(CCB-MAC)协议用于安全信息的传输。当在广播期间节点没有接收到安全信息时,被选择的辅助节点重传先前侦听到的安全信息到目的节点,并且重传是在未被预留的时隙中进行的,这将不会中断正常的传输。数值分析和仿真结果表明,CCB-MAC明显提高了安全信息传输成功的概率,降低了传输时延和丢包率。展开更多
基金Supported by National Natural Scientific Foundation of China,No.81025015 and 91129301
文摘Antiviral treatment is the only option to prevent or defer the occurrence of hepatocellular carcinoma(HCC) in patients chronically infected with hepatitis B virus(HBV) or hepatitis C virus(HCV). The approved medication for the treatment of chronic HBV infection is interferon-α(IFNα) and nucleos(t)ide analogues(NAs), including lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir disoproxil fumarate. IFNα is the most suitable for young patients with less advanced liver diseases and those infected with HBV genotype A. IFNα treatment significantly decreases the overall incidence of HBV-related HCC in sustained responders. However, side effects may limit its long-term clinical application. Orally administered NAs are typically implemented for patients with more advanced liver diseases. NA treatment significantly reduces disease progression of cirrhosis and therefore HCC incidence, especially in HBV e antigen-positive patients. NA-resistance due to the mutations in HBV polymerase is a major limiting factor. Of the NA resistance-associated mutants, A181 T mutant significantly increases the risk of HCC development during the subsequent course of NA therapy. It is important to initiate treatment with NAs that have a high genetic barrier to resistance, to counsel patients on medication adherence and to monitor virological breakthroughs. The recommended treatment for patients with chronic HCV infection is peg-IFN plus ribavirin that can decrease the occurrence of HCC in those who achieve a sustained virological response and have not yet progressed to cirrhosis. IFN-based treatment is reserved for patients with decompensated cirrhosis who are under evaluation of liver transplantation to reduce post-transplant recurrence of HCV. More effective therapeutic options such as direct acting antiviral agents will hopefully increase the response rate in difficult-totreat patients with HCV genotype 1. However, the risk of HCC remains in cirrhotic patients(both chronic HBV and HCV infection) if treatment is initiated after cirrhosis is established. Future research should focus on investigating new agents, especially for those patients with hepatic decompensation or post-transplantation.
文摘The structure and electrochemical properties of the La0.7Mg0.3Ni3.4-xMn0.1Cox （x=01.05） hydrogen storage alloys were investigated. The crystal structure and the lattice parameters of the alloys were analyzed by X-ray diffractometry and Rietveld method. Electrochemical properties of the alloys including p—c—t curves, discharge capacity, discharge capacity retention were studied. The results show that （La, Mg）Ni3 and LaNi5 are the main phases of all the alloys. The plateau pressure for hydrogen absorption/desorption decreases and the hydrogen storage capacity firstly increases and subsequently decreases with increasing Co content. The values of the maximum discharge capacity of the alloy electrodes remain in range of 395.3403.1mA·h/g in spite of the change of Co content. The cycling stability of the alloy electrodes is greatly improved with increasing Co content, which is attributed to the suppression of the cell volume expansion during hydriding, leading the pulverization of the alloy particles lowered and the oxidation/corrosion of the active elements reduced.
文摘针对测地线活动轮廓(geodesic active contour,GAC)模型轮廓演化速度慢的问题,构造一个区域灰度相似性信息项,对GAC模型的能量泛函进行改进,加快轮廓演化速度,将其用于肺部薄扫CT(computed tomography)图像序列中肺实质的自动分割。采用基于Nystrom逼近的谱聚类算法分割CT图像序列中间位置CT中的肺实质,计算其灰度均值与标准差,构造区域灰度相似性信息项,以分割好的肺实质轮廓作为初始轮廓,分别从上下两个方向采用改进了能量泛函的GAC模型实现其它切片中肺实质的分割。实验结果表明,该方法能够较好实现肺实质的自动分割,与医师分割结果的重合率可达94.83%,时间消耗较少。
文摘目的探讨16排螺旋CT行胸部血管造影检查时图像质量与碘造影剂注射流速的相关性。方法选取自2013年10月—2016年9月在该科行胸部CT检查老年患者90例,随机分为A1、A2、A3 3组,每组30例。3组流速分别为2.0~2.4、2.5~2.8、2.9~3.2 m L/s。观察分析肺动脉平均强化值,图像质量。结果 3组行CT检查后的效果评价A1,A2,A3组的肺动脉平均强化值分别为(195.9±29.1),(262.20±59.0),(255.9±53.2),3组造影效果主动脉强化值差异有统计学意义(P<0.01),3组不同流速碘造影剂的图像质量差异有统计学意义(P<0.01)。结论老年患者在行胸部CT增强扫描碘造影剂注射流速在2.5~2.8 m L/s时,获得的图像较满意,并能满足临床诊断需要,且能保护患者穿刺血管的安全。
文摘随着无线通信技术的发展,车载自组织网络(Vehicular Ad Hoc Network,VANET)已经成为一个新型的研究领域。针对VANET中车辆行驶的特征以及车辆间安全信息传输严格的时延限制和高可靠性要求,提出了一种基于簇的协作MAC(CCB-MAC)协议用于安全信息的传输。当在广播期间节点没有接收到安全信息时,被选择的辅助节点重传先前侦听到的安全信息到目的节点,并且重传是在未被预留的时隙中进行的,这将不会中断正常的传输。数值分析和仿真结果表明,CCB-MAC明显提高了安全信息传输成功的概率,降低了传输时延和丢包率。
